EDA and X-linked hypohidrotic ectodermal dysplasia: Meanwhile, researchers found that prenatal ultrasound-guided intra-amniotic injections [82] or the postnatal intravenous administration of soluble recombinant EDA (Fc: EDA1) [65] can efficiently modify the disease development in the XLHED animal models [65,66].